Drugs / HP3
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00613665 | Feb → Dec 2001 | Helicobacter pylori infectious disease, gastric cancer, gastritis, lymphoma +1 | Novartis Vaccines | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05537519 | May → Jul 2023 | urinary tract infection | Unity Health Toronto | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HP3 | “Experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,2 month schedule (alum control was administered at 4...” NCT00613665 ↗1“3-phage cocktail comprised of HP3, HP3.1 and ES19” NCT05537519 ↗ |
| Modality | Other / unclassified | “3-phage cocktail comprised of HP3, HP3.1 and ES19” NCT05537519 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT00613665 ↗ |